Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

被引：1
|
作者：
Lachowiez, Curtis A. [1 ]
Ravikumar, Vishvaas I. [1 ]
Othman, Jad [1 ,2 ,3 ,4 ]
O'Nions, Jenny [2 ,5 ]
Peters, Daniel T. [3 ,6 ]
Mcmahon, Christine [7 ]
Swords, Ronan [1 ]
Cook, Rachel [1 ]
Saultz, Jennifer N. [1 ]
Tyner, Jeffrey W. [1 ]
Dillon, Richard [2 ,3 ]
Zeidner, Joshua F. [6 ]
Pollyea, Daniel A. [7 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol Med Oncol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA
[2] Kings Coll London, Dept Med & Mol Genet, London, England
[3] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
[4] Univ Sydney, Fac Med & Hlth, Sydney, Australia
[5] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England
[6] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[7] Univ Colorado, Sch Med, Div Hematol, Aurora, CO USA
来源：
BLOOD | 2024年 / 144卷 / 26期
关键词：
AZACITIDINE;
D O I：
10.1182/blood.2024026925
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2788 / 2792
页数：5
相关论文
共 50 条
  • [21] Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy
    Pollyea, Daniel A.
    Winters, Amanda
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    BLOOD, 2020, 136
  • [22] Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
    Stahl, Maximilian
    Menghrajani, Kamal
    Derkach, Andriy
    Chan, Alexander
    Xiao, Wenbin
    Glass, Jacob
    King, Amber C.
    Daniyan, Anthony F.
    Famulare, Christopher
    Cuello, Bernadette M.
    Horvat, Troy Z.
    Abdel-Wahab, Omar
    Levine, Ross L.
    Viny, Aaron D.
    Stein, Eytan M.
    Cai, Sheng F.
    Roshal, Mikhail
    Tallman, Martin S.
    Goldberg, Aaron D.
    BLOOD ADVANCES, 2021, 5 (05) : 1552 - 1564
  • [23] ELN Genetic Risk Stratification Not Affect the Mid-Term Survival in Childhood AML: Report from Southern China Childhood AML Group
    Feng, Xiaoqin
    Li, Jian
    He, Xiangling
    Xu, Honggui
    Zheng, Mincui
    Wen, Hong
    He, Yingyi
    Liu, Sixi
    Ruan, Yongsheng
    Li, Chunfu
    BLOOD, 2018, 132
  • [24] Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy
    Chow, Lydia D.
    Chen, Denaly
    Vergara-Lluri, Maria E.
    Tam, Eric
    Woan, Karrune
    Chaudhary, Preet M.
    Yaghmour, George
    Ladha, Abdullah
    BLOOD, 2022, 140 : 9027 - 9028
  • [25] Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy
    Kristensen, Daniel Tuyet
    Brondum, Rasmus Froberg
    orskov, Andreas Due
    Marcher, Claus Werenberg
    Schollkopf, Claudia
    Sorensen, Anne Louise Tolboll
    Severinsen, Marianne Tang
    Bogsted, Martin
    Roug, Anne Stidsholt
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (04) : 573 - 582
  • [26] Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
    Othman, Jad
    Tiong, Ing S.
    'Nions, Jenny
    Dennis, Mike
    Mokretar, Katya
    Ivey, Adam
    Austin, Michael
    Latif, Anne -Louise
    Amer, Mariam
    Chan, Wei Yee
    Crawley, Charles
    Crolla, Francesca
    Cross, Joe
    Dang, Ray
    Elliot, Johnathon
    Fong, Chun Y.
    Galli, So fia
    Gallipoli, Paolo
    Hogan, Francesca
    Kalkur, Pallavi
    Khan, Anjum
    Krishnamurthy, Pramila
    Laurie, John
    Loo, Sun
    Marshall, Scott
    Mehta, Priyanka
    Murthy, Vidhya
    Nagumantry, Sateesh
    Pillai, Srinivas
    Potter, Nicola
    Sellar, Rob
    Taylor, Tom
    Zhao, Rui
    Russell, Nigel H.
    Wei, Andrew H.
    Dillon, Richard
    BLOOD, 2024, 143 (04) : 336 - 341
  • [27] ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
    Buccisano, Francesco
    Palmieri, Raffaele
    Piciocchi, Alfonso
    Arena, Valentina
    Candoni, Anna
    Melillo, Lorella
    Calafiore, Valeria
    Cairoli, Roberto
    de Fabritiis, Paolo
    Storti, Gabriella
    Salutari, Prassede
    Lanza, Francesco
    Martinelli, Giovanni
    Luppi, Mario
    Capria, Saveria
    Maurillo, Luca
    Del Principe, Maria Ilaria
    Paterno, Giovangiacinto
    Consalvo, Maria Antonietta Irno
    Ottone, Tiziana
    Lavorgna, Serena
    Voso, Maria Teresa
    Fazi, Paola
    Vignetti, Marco
    Arcese, William
    Venditti, Adriano
    BLOOD ADVANCES, 2022, 6 (08) : 2510 - 2516
  • [28] Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine
    Zhang, Lei-Si
    Wang, Jun
    Xu, Ming-Zhu
    Wu, Tian-Mei
    Huang, Si-Man
    Cao, Han-Yu
    Sun, Ai-Ning
    Liu, Song-Bai
    Xue, Sheng-Li
    ONCOTARGETS AND THERAPY, 2022, 15 : 159 - 164
  • [29] Genetic Mutation and Outcome of Venetoclax-Based Therapy in Newly Diagnosed AML in the Real World: Hokkaido Leukemia Net Study
    Miyashita, Naoki
    Onozawa, Masahiro
    Nagai, Jun
    Yoshida, Shota
    Kimura, Hiroyuki
    Matsukawa, Toshihiro
    Hirabayashi, Shinsuke
    Mori, Akio
    Kondo, Takeshi
    Hidaka, Daisuke
    Minauchi, Koichiro
    Shigematsu, Akio
    Hashiguchi, Junichi
    Igarashi, Tetsuyuki
    Kakinoki, Yasutaka
    Tsutsumi, Yutaka
    Iwasaki, Hiroshi
    Yokoyama, Shota
    Wakasa, Kentaro
    Fujimoto, Katsuya
    Ishihara, Toshimichi
    Sakai, Hajime
    Iyama, Satoshi
    Oyake, Tatsuo
    Teshima, Takanori
    BLOOD, 2023, 142
  • [30] DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy
    Albitar, Maher
    Ip, Andrew
    Goy, Andre H.
    Linder, Katherine
    Estella, Jeffrey Justin
    Charifa, Ahmad
    Ma, Wanlong
    Pecora, Andrew L.
    Koprivnikar, Jamie
    McCloskey, James
    BLOOD, 2022, 140 : 6270 - 6271
12345